Theradiag and UCB Enter into a Master Services Agreement

Regulatory News :

Theradiag (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announces today that it has entered into a master services agreement with the biopharmaceutical company UCB, with a first application for the anti-TNF biologic certolizumab pegol (the brand name Cimzia®).

Under the terms of the master services agreement, Theradiag will perform services for UCB on a project basis. A first project has already been conducted to determine the comparability of Theradiag’s LISA TRACKER tests with tests performed by UCB in clinical trials for the monitoring of drug levels and anti-drug antibodies in human plasma. The results of this performance study confirmed the suitability of Theradiag’s theranostic kit for monitoring patients treated with certolizumab pegol. The study was sponsored by UCB.

"We are extremely pleased to have entered into this services agreement with UCB, one of the leading biopharmaceutical companies engaged in the treatment of auto-immune diseases. The success of the performance study shows that LISA TRACKER tests could potentially be included in pharmaceutical clinical trials in the future. This is excellent news for our research teams who have developed the theranostics kits, as well as for our investors, since this agreement constitutes a driver of growth for Theradiag’s theranostics sales in Europe and the rest of the world” commented Michel Finance, Chief Executive Officer of Theradiag.

About Theradiag
Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of HIV/AIDS and rectal cancer. Theradiag is thus participating in the development of "customized treatment”, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 70 employees.

For more information about Theradiag, please visit our website: www.theradiag.com